Search

Your search keyword '"Moriarty, P.M."' showing total 3 results
Start Over Author "Moriarty, P.M." Topic cardiology and cardiovascular medicine
3 results on '"Moriarty, P.M."'

1. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

Author

Moriarty, P.M., Steg, P.G., McGinniss, J., Zeiher, A.M., White, H.D., Manvelian, G., Pordy, R., Loy, M., Jukema, J.W., Harrington, R.A., Gray, J.V., Gorby, L.K., Goodman, S.G., Diaz, R., Bittner, V.A., Bhatt, D.L., Szarek, M., Schwartz, G.G., and ODYSSEY OUTCOMES Investigators

Subjects
Erythrocytes, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Cholesterol, LDL, major adverse cardiovascular events, Treatment Outcome, Risk Factors, Internal Medicine, Humans, acute coronary syndromes, Acute Coronary Syndrome, red blood cell distribution width, Cardiology and Cardiovascular Medicine, Alirocumab
Abstract

Elevated red blood cell distribution width (RDW) is associated with increased risk for major adverse cardiovascular events (MACE) and death in patients with cardiovascular disease. The ODYSSEY OUT-COMES trial compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome (ACS) and elevated atherogenic lipoproteins despite optimized statin treatment. This post hoc analysis determined whether RDW independently predicts risk of MACE and death in patients after recent ACS, whether RDW influences MACE reduction with alirocumab, and whether alirocumab treatment affects RDW. Associations of baseline RDW with risk of MACE and death were analyzed in the placebo group in adjusted proportional hazards models. Interactions of RDW and treatment on the risk of MACE and death were evaluated. An increasing quartile of RDW was associated with characteristics that predicted risk of MACE and death including age, hypertension, diabetes, atherosclerotic conditions and events, revascularizations, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein. After ad-justing for baseline characteristics associated with the risk of MACE or death, baseline RDW remained independently associated with the risk of MACE and death in the placebo group (hazard ratios [95% confidence intervals] 1.08 [1.02-1.15] and 1.13 [1.03-1.24] per 1% increase of RDW, respectively, both p < 0.001). There was no interaction of RDW and treatment on MACE or death, nor did alirocumab affect RDW. RDW was associated with an increased risk of MACE and death, independent of established risk factors.(c) 2022 National Lipid Association. Published by Elsevier Inc.This is an open access article under the CC BY-NC-ND license( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Published
2022
Full Text
View/download PDF

2. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP)

Author

Massimiliano Ruscica, Peter E. Penson, Nicola Ferri, Cesare R. Sirtori, Matteo Pirro, G.B. John Mancini, Naveed Sattar, Peter P. Toth, Amirhossein Sahebkar, Carl J. Lavie, Nathan D. Wong, Maciej Banach, Julio Acosta, Mutaz Al-Khnifsawi, Fahad Alnouri, Fahma Amar, Atanas G. Atanasov, Gani Bajraktari, Sonu Bhaskar, Bojko Bjelakovic, Eric Bruckert, Richard Ceska, Arrigo F.G. Cicero, Xavier Collet, Olivier Descamps, Dragan Djuric, Ronen Durst, Marat V. Ezhov, Zlatko Fras, Dan Gaita, Adrian V. Hernandez, Steven R. Jones, Jacek Jozwiak, Nona Kakauridze, Amani Kallel, Niki Katsiki, Amit Khera, Karam Kostner, Raimondas Kubilius, Gustavs Latkovskis, A. David Marais, Seth S. Martin, Julio Acosta Martinez, Mohsen Mazidi, Dimitri P. Mikhailidis, Erkin Mirrakhimov, Andre R. Miserez, Olena Mitchenko, Natalya P. Mitkovskaya, Patrick M. Moriarty, Seyed Mohammad Nabavi, Devaki Nair, Demosthenes B. Panagiotakos, György Paragh, Daniel Pella, Zaneta Petrulioniene, Arman Postadzhiyan, Raman Puri, Ashraf Reda, Željko Reiner, Dina Radenkovic, Michał Rakowski, Jemaa Riadh, Dimitri Richter, Manfredi Rizzo, Maria-Corina Serban, Abdulla M.A. Shehab, Aleksandr B. Shek, Claudia Stefanutti, Tomasz Tomasik, Margus Viigimaa, Pedro Valdivielso, Dragos Vinereanu, Branislav Vohnout, Stephan von Haehling, Michal Vrablik, Hung-I Yeh, Jiang Zhisheng, Andreas Zirlik, Ruscica M, Penson PE, Ferri N, Sirtori CR, Pirro M, Mancini GBJ, Sattar N, Toth PP, Sahebkar A, Lavie CJ, Wong ND, Banach M, International Lipid Expert Panel (ILEP) and International Lipid Expert Panel Experts, Cicero AFG, Ruscica M., Penson P.E., Ferri N., Sirtori C.R., Pirro M., Mancini G.B.J., Sattar N., Toth P.P., Sahebkar A., Lavie C.J., Wong N.D., Banach M., Acosta J., Al-Khnifsawi M., Alnouri F., Amar F., Atanasov A.G., Bajraktari G., Bhaskar S., Bjelakovic B., Bruckert E., Ceska R., Cicero A.F.G., Collet X., Descamps O., Djuric D., Durst R., Ezhov M.V., Fras Z., Gaita D., Hernandez A.V., Jones S.R., Jozwiak J., Kakauridze N., Kallel A., Katsiki N., Khera A., Kostner K., Kubilius R., Latkovskis G., Marais A.D., Martin S.S., Martinez J.A., Mazidi M., Mikhailidis D.P., Mirrakhimov E., Miserez A.R., Mitchenko O., Mitkovskaya N.P., Moriarty P.M., Nabavi S.M., Nair D., Panagiotakos D.B., Paragh G., Pella D., Petrulioniene Z., Postadzhiyan A., Puri R., Reda A., Reiner Z., Radenkovic D., Rakowski M., Riadh J., Richter D., Rizzo M., Serban M.-C., Shehab A.M.A., Shek A.B., Stefanutti C., Tomasik T., Viigimaa M., Valdivielso P., Vinereanu D., Vohnout B., von Haehling S., Vrablik M., Yeh H.-I., Zhisheng J., Zirlik A., and UCL - (SLuc) Service de pathologie cardiovasculaire

Subjects
RM, Arterial disease, Anti-Inflammatory Agents, Inflammation, Disease, C-reactive protein, cardiovascular disease, inflammation, nutraceuticals, omega-3, position paper, red-yeast rice, 030204 cardiovascular system & hematology, Bioinformatics, Systemic inflammation, 03 medical and health sciences, 0302 clinical medicine, Nutraceutical, Medicine, Humans, Position paper, 030212 general & internal medicine, Uncategorized, Omega-3, biology, Cardiovascular disease, Nutraceuticals, Red-yeast rice, Biomarkers, Cardiovascular Diseases, Lipids, Dietary Supplements, Vascular inflammation, business.industry, C-reactive protein, Cardiovascular disease, Inflammation, Nutraceuticals, Omega-3, Position paper, Red-yeast rice, Anti-Inflammatory Agents, Biomarkers, Cardiovascular Diseases, Humans, Inflammation, Lipids, Dietary Supplements, biology.protein, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not enough evidence to confirm this. Indeed, diet is an important lifestyle determinant of health and can influence both systemic and vascular inflammation, to varying extents, according to the individual nutraceutical constituents. Thus, the aim of this Position Paper is to provide the first attempt at recommendations on the use of nutraceuticals with effective anti-inflammatory properties.

Published
2021

3. The Role of Nutraceuticals in Statin Intolerant Patients

Author

Dimitri P. Mikhailidis, Michel Langlois, Maria-Corina Serban, Rosaria Vincenza Giglio, György Paragh, G.B. John Mancini, Eric Bruckert, Zlatko Fras, Bernhard Paulweber, Daniel Pella, Michal Vrablík, Paul Muntner, Olivier S. Descamps, Gani Bajraktari, Arrigo F G Cicero, Marat V. Ezhov, Željko Reiner, Giuseppe M.C. Rosano, Olena Mitchenko, Angelo Maria Patti, Christos Pitsavos, Patrick M. Moriarty, Dragana Nikolic, Manfredi Rizzo, Nathan D. Wong, Jacek Rysz, Gerald F. Watts, Niki Katsiki, Robert S. Rosenson, Demosthenes B. Panagiotakos, Maciej Banach, Stephan von Haehling, Dragan M. Djuric, Atanas G. Atanasov, Amirhossein Sahebkar, Gustavs Latkovskis, Dragos Vinereanu, UCL - (SLuc) Service de pathologie cardiovasculaire, Banach M., Patti A.M., Giglio R.V., Cicero A.F.G., Atanasov A.G., Bajraktari G., Bruckert E., Descamps O., Djuric D.M., Ezhov M., Fras Z., von Haehling S., Katsiki N., Langlois M., Latkovskis G., Mancini G.B.J., Mikhailidis D.P., Mitchenko O., Moriarty P.M., Muntner P., Nikolic D., Panagiotakos D.B., Paragh G., Paulweber B., Pella D., Pitsavos C., Reiner Z., Rosano G.M.C., Rosenson R.S., Rysz J., Sahebkar A., Serban M.-C., Vinereanu D., Vrablik M., Watts G.F., Wong N.D., Rizzo Manfredi, and Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M

Subjects
Statin, medicine.drug_class, Disease, cardiovascular risk, dyslipidemia, nutraceuticals, position paper, statin intolerance, 030204 cardiovascular system & hematology, Bioinformatics, Klinikai orvostudományok, 03 medical and health sciences, 0302 clinical medicine, Nutraceutical, Ezetimibe, Statin intolerance, Red yeast rice, Medicine, Humans, Position paper, 030212 general & internal medicine, Endothelial dysfunction, Dyslipidemias, business.industry, Clinical Studies as Topic, Orvostudományok, medicine.disease, Cardiovascular risk, 3. Good health, Dyslipidemia, Dietary Supplements, Arterial stiffness, lipids (amino acids, peptides, and proteins), nutraceutical, Hydroxymethylglutaryl-CoA Reductase Inhibitor, Nutraceuticals, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, medicine.drug, Human
Abstract

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results